评估转移性去势抵抗性前列腺癌（mCRPC）患者接受多西他赛联合卡铂治疗的疗效和安全性。

回顾性分析2017年5月至2022年8月在北京大学第一医院治疗的36例mCRPC患者的临床资料。患者中位年龄68岁（44~80岁），病理类型均为腺泡腺癌，经影像学证实存在远处转移，并接受至少2周期多西他赛联合卡铂治疗。记录治疗期间前列腺特异性抗原（PSA）最好应答、影像学应答、不良反应并进行分析。

36例患者中位接受治疗周期数为6周期（2~10周期），其中PSA降低超过50%的患者（PSA50）为50%（18/36），治疗期间PSA稳定患者（降低0~30%）16.7%（6/36）；治疗期间综合评估PSA、症状以及肿瘤影像学判定疾病进展9例（25%）；治疗的主要不良反应（AE）为骨髓抑制（26/36例）、胃肠道反应、乏力等；其中严重不良事件3例，6例（16.7%）患者因不可耐受的AE停药。

多西他赛联合卡铂方案对新型内分泌及多西他赛化疗后耐药的mCRPC具有良好的PSA应答率和疾病控制率，治疗过程中严重不良反应发生率较低。

To evaluate the efficacy and safety of docetaxel combined with carboplatin in patients with metastatic castration resistant prostate cancer (mCRPC).

The clinical data of 36 patients with mCRPC who had been treated at the Peking University First Hospital from May 2017 to August 2022 were retrospectively analyzed. The median age was 68 years (range, 44-80 years). The pathological type in all patients was acinar adenocarcinoma with distant metastasis confirmed by bone scan and/or PET/CT scan, and all the patients received at least two cycles of docetaxel plus carboplatin therapy. The best prostate specific antigen (PSA) response, imaging response, and adverse events during treatment were recorded and analyzed.

The median number of treatment cycles was 6 (range, 2-10) cycles. The PSA decreased by more than 50% (PSA 50) in 18 patients (50.0%), and the PSA kept stable (decreased by 0-30%) in 6 cases (16.7%). During the treatment, 9 cases (25%) were assessed as disease progression by comprehensive assessment of PSA, symptoms, and tumor imaging. The most common adverse events (AEs) were myelosuppression (26/36 cases), nausea, fatigue, etc. Serious adverse events occurred in 3 patients, and 6 (16.7%) patients stopped the treatment permanently due to intolerable AE.

Docetaxel plus carboplatin regimen has a good PSA response rate and disease control rate for mCRPC that has progressed on androgen receptor pathway inhibitors and docetaxel. The incidence of serious adverse reactions during the treatment is low.